lunes, 17 de abril de 2017

Childhood Craniopharyngioma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Craniopharyngioma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version



SECTIONS









Changes to This Summary (04/14/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that regardless of the treatment modality, long-term event-free survival is approximately 65% in children, with 5-year and 10-year overall survival rates higher than 90%.
Added Maarouf et al. as reference 8.
Revised text to state that vasculopathies and subsequent strokes may result from local irradiation. Also added text to state that one cross-sectional cohort study observed a trend suggesting that long-term growth hormone replacement may reduce the risk of stroke.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: April 14, 2017

No hay comentarios:

Publicar un comentario